Allopurinol/verinurad - Astrazeneca
Alternative Names: Verinurad/allopurinol - AstraZenecaLatest Information Update: 28 May 2024
At a glance
- Originator AstraZeneca
- Class Naphthalenes; Propionic acids; Purines; Pyrazoles; Pyridines; Pyrimidines; Pyrimidinones; Small molecules; Uricosurics; Urologics
- Mechanism of Action SLC22A12 protein inhibitors; Xanthine oxidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Renal failure
Most Recent Events
- 28 May 2024 No recent reports of development identified for phase-I development in Renal-failure in Germany (PO, Capsule)
- 15 Jul 2021 AstraZeneca completes a phase I bioavailability trial in Renal failure (In volunteers) in Germany (PO, Capsule) (NCT04550234)
- 15 Sep 2020 AstraZeneca plans a phase I trial in Renal failure (In volunteers) in Germany in October 2020 (NCT04550234)